Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2023-12-14 00:00:00 ET · period of report 2023-12-12 · accession 0001883850-23-000100 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-12-14 | 2023-12-12+ | REGN | Landry Robert E | EVP Fin CFO | F - Tax | $858.18 | -7,104 | 21.1K | -25% | -$6.10M |
| D | 2023-12-14 | 2023-12-13 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $378.98 | +1,000 | 22.1K | +5% | +$379.0K |
| D | 2023-12-14 | 2023-12-13 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $0.00 | -1,000 | 19.3K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-13 | F | D | 723 | $871.12 | 21,361 | D | — | — | |
| 2 | Common | Common Stock | 2023-12-12 | F | D | 6,381 | $856.71 | 21,084 | D | — | — | |
| 3 | Common | Common Stock | 2023-12-13 | M | A | 1,000 | $378.98 | 22,084 | D | — | — | |
| 4 | Derivative | Non-Qualified Stock Option (right to buy) | 2023-12-13 | M | D | 1,000 | $0.00 | 19,337 | D | $378.98 · — to 2027-12-12 | 1,000 Common Stock | (F1) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |